Literature DB >> 9067974

Targeted vectors for gene therapy of cancer and retroviral infections.

W Walther1, U Stein.   

Abstract

Gene therapy has developed to a technology which rapidly moved from the laboratory bench to the bedside in the clinic. This implies safe, efficient and targeted gene transfer systems for suitable application to the patient. Beside the development of such gene transfer vectors of viral or nonviral origin, improvement of cell type specific and inducible gene expression is pivotal for successful gene therapy leading to targeted gene action. Numerous gene therapy approaches for treatment of cancer and retroviral infections utilize cell type specific and/or regulatable promoter and enhancer sequences for the selective expression of therapeutic genes in the desired cell populations and tissues. In this article the recent developments and the potential of expression targeting are reviewed for gene therapy approaches of cancer and retroviral infections.

Entities:  

Mesh:

Year:  1996        PMID: 9067974     DOI: 10.1007/BF02761707

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  61 in total

1.  Molecular cloning and characterization of the promoter region of the calcineurin A alpha gene.

Authors:  C D Chang; T Takeda; H Mukai; H Shuntoh; T Kuno; C Tanaka
Journal:  Biochem J       Date:  1992-12-15       Impact factor: 3.857

Review 2.  Factors controlling the expression of mouse mammary tumour virus.

Authors:  W H Günzburg; B Salmons
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

Review 3.  Human gene therapy.

Authors:  W F Anderson
Journal:  Science       Date:  1992-05-08       Impact factor: 47.728

4.  Beta-casein gene promoter activity is regulated by the hormone-mediated relief of transcriptional repression and a mammary-gland-specific nuclear factor.

Authors:  M Schmitt-Ney; W Doppler; R K Ball; B Groner
Journal:  Mol Cell Biol       Date:  1991-07       Impact factor: 4.272

5.  Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir.

Authors:  T Joki; M Nakamura; T Ohno
Journal:  Hum Gene Ther       Date:  1995-12       Impact factor: 5.695

6.  Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression.

Authors:  H Schrewe; J Thompson; M Bona; L J Hefta; A Maruya; M Hassauer; J E Shively; S von Kleist; W Zimmermann
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

7.  Cells induced to express a human immunodeficiency virus type 1 envelope gene mutant inhibit the spread of wild-type virus.

Authors:  G L Buchschacher; E O Freed; A T Panganiban
Journal:  Hum Gene Ther       Date:  1992-08       Impact factor: 5.695

8.  Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir.

Authors:  Y Manome; M Abe; M F Hagen; H A Fine; D W Kufe
Journal:  Cancer Res       Date:  1994-10-15       Impact factor: 12.701

9.  Selective killing of CD4+ cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected cell population.

Authors:  M Caruso; D Klatzmann
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

10.  Gene therapy for cancer using tumour-specific prodrug activation.

Authors:  J D Harris; A A Gutierrez; H C Hurst; K Sikora; N R Lemoine
Journal:  Gene Ther       Date:  1994-05       Impact factor: 5.250

View more
  1 in total

1.  Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma.

Authors:  R M Diaz; T Eisen; I R Hart; R G Vile
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.